人参皂甙Rg3联合化疗对非小细胞肺癌患者血清血管内皮生长因子的影响及疗效观察
|
摘要
肺癌是目前常见的、死亡率最高的恶性肿瘤之一,综合治疗是提高疗效的重要举措。肿瘤血管生成是肿瘤生长、侵袭和转移的基础,抗血管生成已成为抗肿瘤治疗的研究热点。人参皂甙Rg3是中药人参提取物之一,实验显示具有抑制肿瘤血管生成和肿瘤组织血管内皮生长因子的作用,文献报道与化疗结合具有提高疗效的作用。
目的:1、观察人参皂甙Rg3联合全身化疗对非小细胞肺癌患者血清VEGF影响,探讨其抗肿瘤血管生成的可能机制;2、观察人参皂甙Rg3联合全身化疗对非小细胞肺癌患者的临床疗效。
方法:选取南京军区福州总医院确诊为晚期非小细胞肺癌符合观察标准者41例,随机对照分为2组:A组20例采用全身化疗;B组21例采用人参皂甙Rg3胶囊联合全身化疗。观察瘤体指标、行为状态评分,应用酶联免疫吸附法检测外周血清血管内皮生长因子水平变化。
结果:1、客观疗效:B组近期有效率为33.3%(7/21),A组为20%(4/20)(P＞0.1),B组疾病控制率为76.2%(16/21),A组为45%(9/20)(P＜0.05);2、生活质量:B组生活质量改善率为66.7%(14/21),A组为35%(7/20)(P＜0.05);3、sVEGF水平:①治疗前:Ⅳ期患者的sVEGF水平为324.04±71.61 pg/ml,Ⅲ期患者的为195.33±48.96pg/ml,健康人群为55.20±9.47 pg/ml(P＜0.05);A组sVEGF水平为277.15±97.69pg/ml,B组为276.76±83.07 pg/ml(P＞0.1);②治疗后A组sVEGF水平为243.65±65.64pg/ml,B组为216.33±56.30pg/ml,具有统计学意义(P＜0.05)。
结论:1、人参皂甙Rg3联合全身能进一步下调sVEGF水平,有利于抑制肿瘤新生血管;2、人参皂甙Rg3联合全身化疗具有提高NSCLC患者的近期有效率的趋势,能够提高近期疾病控制率,改善患者生活质量,值得临床进一步观察。
Lung carcinoma is one of the most familiar malignant tumours of international community currently.It has already become the main cause of death of malignant tumors,and the mortality will raise gradually.The growth of tumors is vessel-dependent.Therefore,anti-angiogenetic therapy has become one of the heat points in cancer research fled.Ginsenoside Rg3 is a kind of effective chemical component extracted tracely from the Red Ginseng,which can directly inhibit tumor angiogenesis and induce tumor.It was said that chemotherapy combined with Ginsenoside Rg3 was a logical potentially powerful treatment.
Objectives:1.To evaluate the influence of serum vascular endothelial growth factor on Ginsenoside Rg3 combined with chemotherapy in patients with non-small cell lung cancer,and approach the mechanisms on neovascularization.2.To obvserve the clinical anticancer of Ginsenoside Rg3 plus chemotherapy in non-small cell lung cancer patients;.
Methods:Forty-one patients with non-small lung cancer were selected in Fuzhou general hospital.The patients were randomized into two groups:Group A were treated with systemic chemotherapy,Group B with Ginsenoside Rg3 plus systemic chemotherapy.The gross tumor volume and the score of quality of life was evaluated,and the level of serous vascular endothelial growth factor was detected by using of enzyme linked immunosorbent assay.
Results:1.Curative Effect:The recent response rate was 33.3%(7/21)in group B,and 20% (4/20) in group A(P＞0.1).The disease control rate was 76.2%(16/21)in group B,and 45% (9/20) in group A(P＜0.05).2.Quality of Life:The rate of Quality of Life improvement was66.7%in group B,and 35%(7/20) in group A(P＜0.05).3.sVEGF level:①Before treatment:The level of sVEGF was 324.04±71.61 pg/ml in stageⅣpatients,195.33±48.96 pg/ml in stageⅢ,55.20±9.47 pg/ml in healthy population(P＜0.05).The level of sVEGF was 277.15±97.69 pg/ml in group A,and 276.76±83.07 pg/ml in group B(P＞0.1).②After treatment:The level of sVEGF was 243.65±65.64 pg/ml in group A,and 216.33±56.30 pg/ml in group B,with significant difference(P＜0.05).
Conclusion:1.Ginsenosides Rg3 combined with chemotherapy could morely descended the level of sVEGF,which was the way to strengthen the effect of neovascularization.2. Preliminary results show improvements in response rate and quality of life in Ginsenosides Rg3 combined with chemotherapy.It is worthy to confirm the results in further clinical trials.
目的:1、观察人参皂甙Rg3联合全身化疗对非小细胞肺癌患者血清VEGF影响,探讨其抗肿瘤血管生成的可能机制;2、观察人参皂甙Rg3联合全身化疗对非小细胞肺癌患者的临床疗效。
方法:选取南京军区福州总医院确诊为晚期非小细胞肺癌符合观察标准者41例,随机对照分为2组:A组20例采用全身化疗;B组21例采用人参皂甙Rg3胶囊联合全身化疗。观察瘤体指标、行为状态评分,应用酶联免疫吸附法检测外周血清血管内皮生长因子水平变化。
结果:1、客观疗效:B组近期有效率为33.3%(7/21),A组为20%(4/20)(P＞0.1),B组疾病控制率为76.2%(16/21),A组为45%(9/20)(P＜0.05);2、生活质量:B组生活质量改善率为66.7%(14/21),A组为35%(7/20)(P＜0.05);3、sVEGF水平:①治疗前:Ⅳ期患者的sVEGF水平为324.04±71.61 pg/ml,Ⅲ期患者的为195.33±48.96pg/ml,健康人群为55.20±9.47 pg/ml(P＜0.05);A组sVEGF水平为277.15±97.69pg/ml,B组为276.76±83.07 pg/ml(P＞0.1);②治疗后A组sVEGF水平为243.65±65.64pg/ml,B组为216.33±56.30pg/ml,具有统计学意义(P＜0.05)。
结论:1、人参皂甙Rg3联合全身能进一步下调sVEGF水平,有利于抑制肿瘤新生血管;2、人参皂甙Rg3联合全身化疗具有提高NSCLC患者的近期有效率的趋势,能够提高近期疾病控制率,改善患者生活质量,值得临床进一步观察。
Lung carcinoma is one of the most familiar malignant tumours of international community currently.It has already become the main cause of death of malignant tumors,and the mortality will raise gradually.The growth of tumors is vessel-dependent.Therefore,anti-angiogenetic therapy has become one of the heat points in cancer research fled.Ginsenoside Rg3 is a kind of effective chemical component extracted tracely from the Red Ginseng,which can directly inhibit tumor angiogenesis and induce tumor.It was said that chemotherapy combined with Ginsenoside Rg3 was a logical potentially powerful treatment.
Objectives:1.To evaluate the influence of serum vascular endothelial growth factor on Ginsenoside Rg3 combined with chemotherapy in patients with non-small cell lung cancer,and approach the mechanisms on neovascularization.2.To obvserve the clinical anticancer of Ginsenoside Rg3 plus chemotherapy in non-small cell lung cancer patients;.
Methods:Forty-one patients with non-small lung cancer were selected in Fuzhou general hospital.The patients were randomized into two groups:Group A were treated with systemic chemotherapy,Group B with Ginsenoside Rg3 plus systemic chemotherapy.The gross tumor volume and the score of quality of life was evaluated,and the level of serous vascular endothelial growth factor was detected by using of enzyme linked immunosorbent assay.
Results:1.Curative Effect:The recent response rate was 33.3%(7/21)in group B,and 20% (4/20) in group A(P＞0.1).The disease control rate was 76.2%(16/21)in group B,and 45% (9/20) in group A(P＜0.05).2.Quality of Life:The rate of Quality of Life improvement was66.7%in group B,and 35%(7/20) in group A(P＜0.05).3.sVEGF level:①Before treatment:The level of sVEGF was 324.04±71.61 pg/ml in stageⅣpatients,195.33±48.96 pg/ml in stageⅢ,55.20±9.47 pg/ml in healthy population(P＜0.05).The level of sVEGF was 277.15±97.69 pg/ml in group A,and 276.76±83.07 pg/ml in group B(P＞0.1).②After treatment:The level of sVEGF was 243.65±65.64 pg/ml in group A,and 216.33±56.30 pg/ml in group B,with significant difference(P＜0.05).
Conclusion:1.Ginsenosides Rg3 combined with chemotherapy could morely descended the level of sVEGF,which was the way to strengthen the effect of neovascularization.2. Preliminary results show improvements in response rate and quality of life in Ginsenosides Rg3 combined with chemotherapy.It is worthy to confirm the results in further clinical trials.
引文
[1]高勇,王杰军.人参皂甙Rg3抑制肿瘤新生血管形成的研究[J].第二军医大学学报,2001,22(1):40-42.
[2]陈明伟,杨岚,倪磊,等.Rg3对人肺腺癌A549细胞及其内源性VEGF的影响[J].四川大学学报(医学版),2006;37(1):60-62.
[3]孙燕,林洪生,朱允中,等.长春瑞滨合并顺铂(NP)加参一胶囊或安慰剂治疗晚期非小细胞肺癌的多中心双盲随机临床研究报告[J].中国肺癌杂志,2006,9(3):254-258.
[4]American Cancer Society.Cancer Facts and Figueres 2006.Atlanta:American Cancer Sciety.2006:13-14.
[5]汤钊猷.现代肿瘤学[M],第2版上海:复旦大学出版社,2003,3.
[6]孙燕,周际昌.临床肿瘤内科手册[M],第4版北京:人民卫生出版社,2003:563-566.
[7]Martins SJ,Pereia JR.Clinical factors and prognosis in non-small cell lung cancer[J].Am J Clin Oncol,1999,22(5):453.
[8]Auerbach R,Lewis R,Shinners B,et al.Angiogensis assays:a critical overview[J].Clin Chem.2003,49(1):32-40.
[9]Hurvitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metasratic correctal cancer[J].Nev Engl J Med,2004,350(23):2335-2342.
[10]李树婷,孙燕.肿瘤血管抑制剂的研究历史,现状和发展前景[J].癌症进展,2003,6(1):801.
[11]Iishu H,Tatsuta M,Baba M,et al.Inhibition by ginsenoside Rg3 of bombesin induced by azoxymethane in Wistar rats[J].Clin Exp Metastasis,1997,15(6):603-611.
[12]史美祺,冯继峰,潘良熹,等.参一胶囊辅助化疗治疗晚期非小细胞肺癌临床观察[J].临床肿瘤学杂志,2006,11(3):193-194.
[13]陈明伟,杨岚,倪磊,等.Rg3对人肺腺癌A549细胞及其内源性VEGF的影响.四川大学学报(医学版),2006:37(1):60-62.
[14]Kato Y,Asano K,Mogi T,et al.Clinical significance of circulaxing vascular endothelial growth factor in dogs with mammarg gland tumors[J].Vet Med Sci,2007,69(1):77-80.
[15]Matsuyama W,Hashiguehi T,MizoguehiI A.Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer[J].Chest,2000,118(4):948-951.
[16]Shimanuki Y,Takahashi K,Cui R,et al.Role of serum vascular endothelial growth factor dependent in prediction of angiogenesis and prognosis for non-small cell lung cancer[J].Lung,2005,183(1):29-42.
[17]孙燕,石远凯.临床肿瘤内科手册[M],第5版北京:人民卫生出版社,2007:417-418.
[18]孙燕,石远凯.临床肿瘤内科手册[M],第5版北京:人民卫生出版社,2007:388.
[19]Non-small-cell Lung Cancer Collaborative Group:Chemotherapy in non-small-cell lung cancer:A meta-analysis using updated data on individual patients from 52 randomized clinical trials[J].British Medical Journal,1995,311(7010):899-909.
[20]吴银松,王臻.多西紫杉醇联合健择治疗晚期非小细胞肺癌的系列评价[]].第四军医大学学报,2004:25(3):278-281.
[21]臧爱华,于丁,柯玉华,等.我国晚期非小细胞肺癌化疗作用现状分析[J].中国肿瘤,2005,14(9):612.
[22]Folkman J,Beckner K,Angiogenesis imaging,Acad Radiol,2000,7(10):783-785.
[23]Sanderson RD.Heparan sulfate proteoglycans in vasion and metastasis[J].Semin Cell Dev Biol.2001.12(2).89.
[24]李树婷,孙燕.肿瘤血管抑制剂的研究历史、现状和发展前景[J].癌症进展,2003,1:80-87.
[25]王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究.中国肺癌杂志,2005,8(4):283-290.
[26]Tao X,Tang D.Advances in the study of tumor angiogenesis and anti-angiogenic Chinese herbal drugs[J].Chin Materia Medica,2003:26(5):379-381.
[27]Shinkai K,Akedo H,Mukai M,et al.Inhibition of in vitro tumor cell invasion by ginsenoside Rg3[J].Jpn J Cancer Res,1996;87(4):357-362.
[28]林洪生,李炳奎,李树奇.参一胶囊治疗肺癌Ⅱ期临床试验总结[J].中国肿瘤临床,2002,29(4):276-279.
[29]陈明伟,陈建,姚煜,等.人参皂甙20(R)-Rg3治疗肺癌的临床疗效观察[J].西安交通大学学报(医学版),2003,24(3):233.
[30]PerraraN,Davis-smyth T et al.Thebiology of vascular endothelial growth factor.Endocr Rev,1997,18:4-25.
[31]Park J,Keller GA,Ferrara N,et al.The vascular endothelial growth factor(VEGF)is of forms:differential deposition into thesubeithelial extracelluar matrix and bioactivity of extracelluar maxtrix-bound VEGF[J].Mol Biol Cell,1993,4:1317.
[32]张伟,王洁,刘叙仪,等.血管内皮生长因子/碱性成纤维细胞生长因子在非小细胞肺癌中的表达及临床意义[J].中国肿瘤临床,2002,29(4):5-9.
[33]吴宝新,邱志强,战忠利,等.MVD及VEGF、TGFβ-1表达与肺癌转移预后之间的关系[J].中国肿瘤临床,2003,30(10):21-24.
[34]余辉,吴一龙,戎铁华,等.p53、c-erB-2、VEGF蛋白表达对非小细胞肺癌辅助化疗的临床预测[J].中国肿瘤临床,2003,30(1):5-8.
[35]Nicosia RF.What is the role of vascular endothelial growth factor related molecules in tumor angiogenesis?[J].Am J Pathol,1998;153(1):11.
[36]Whittle C,Gillespie K,Harrison R,et al.Heterogeneous vascular endothelial growth factor(VEGF)isoform mRNA and receptor mRNA expression in human glomeruli,and the identification of VEGF148 Mrna,a novel truncated splice variant[J].Clin Sci(lond) 1999;97(3):303.
[37]董强刚,冯久贤,黄进肃,等.血管内皮生长因子对非小细胞肺癌血道转移的影响[J].中华肿瘤杂志,2002,24:142-146.
[38]朱玮.血管内皮生长因子(VEGF)在乳腺癌中的研究进展[J].中国临床医学,2003,(10)6:933-937.
[39]王友良,周民,陈涛.50例肺癌患者血清VEGF、p53含量的分析[J].现代肿瘤学,2005,13(6):811-812.
[40]蒋永新,伍治平,陈晓群,等.肺癌患者血清VEGF水平的临床研究[J].肿瘤防治研究,2005,32(8):526.
[41]朱光君,熊正文,李红伟,等.血管内皮生长因子在非小细胞肺癌中的表达及意义[J].实用医技杂志,2006,13(2):9-11.
[42]刘玉春,林士军,董惠翔,等.肺癌血清血管内皮生长因子水平与分期及预后的关系[J].中国肿瘤,2005,14(3):58-60.
[43]Tao X,Tang D.Advances in the study of tumor angiogenesis and anti-angiogenic Chinese herbal drugs.J Chin Materia Medica,2003:26(5):379-381.
[44]Shinkai K,Akedo H,Mukai M,et al.Inhibition of in vitro tumor cell invasion by ginsenoside Rg3.Jpn J Cancer Res,1996;87(4):357-362.
[45]Mochizuki M,Yoo YC,Matsuzawa K,et al.Inhibitory effect of tumor metastasis in mice by saponins,ginsenoside-Rb2,20(R)-2and20(S)-ginsenoside-Rg3 of red ginseng.Biol Pharm Bull 1995;18(9):1197-1202.
[46]高勇,王杰军,许青.人参皂甙Rg3抑制肿瘤新生血管形成机制研究.肿瘤防治究,2001,28(3):179-181.
[47]潘子民,叶大风,谢幸.人参皂甙Rg3对荷卵巢癌的严重联合免疫缺陷鼠的抗肿瘤血管生成作用的研究.中华妇产科杂志,2002,37(4):227.
[48]陈明伟,杨岚,倪磊,等.Rg3对人肺腺癌A549细胞及其内源性VEGF的影响.四川大学学报(医学版),2006;37(1):60-62.
[49]胡小梅,张培彤,杨宗燕,等.中晚期非小细胞肺癌患者中医证型分布规律研究[J].中国肿瘤,2007,16(1):51-53.
[1]Shimizu K,Asai T,Oku N.Antineovascular therapy,a novel antian-giogenic approach[J].Expert Op in Ther Targets,2005,9(1):63-76.
[2]Baillie C T,Winslet M C,Bradley N J.Tumor Vasculaturapotential therapeutic target[J].Br J Cancer,1995,27(3):257
[3]Rafii S,Lyden D,Benezra R,et al.Vascular and haematopoietic stem cells:novel targets for antiangio- genesis therapy? Nat Rev Cancer,2002,2(11):826-835
[4]Caduff JH,Fischer LC,Burri PH.Scanning electron microscope study of the devloping microvasculature in the postnatal rat lung.Anat Rec,1986,216(2):826-835
[5]Crivellato E,Nico B,Vacca A,et al.Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo.Leukemia,2004,18(2):331-336
[6]Burri PH,Hlushchuk R,Djonov V.Intussusceptive angiogenesis:its emergence,its characteristics,and its significance.Dev Dyn,2004,231(3):474-488
[7]Maniotis AJ,Folberg R,Hess A,et al.Vascular channel formation by human melanoma cells in vitro:vascuiogenie mimicry[J].Am J Parhol,1999,155(3):739-752
[8]Angela RH,Elisabeth AS,Lynn MG,et al.Molecular Regulation of Tumor Cell Vaseulogenic Mimicry by Tyrosine Phosphoryladon:Role of Epithelial Cell Kinase(Eck / EphA2)[J].Cancer Res,2001,61:3250-3255.
[9]Hendrix M J,Seftor E A,Hess A R,et al.Vasculogenic mimicry and tumour-cell plasticity:lessons from melanoma[J].Nat Rev Cancer,2003,3(6):411-421.
[10]Lee LM,Seftor EA,Bonde G,et al.The fate of human malignant melanoma cells transplanted into zebrafish embryos assessment of migration and cell division in the absence of tumor formation[J].Dev Dyn,2005,2334:1560-1570.
[11]Anil KS,Mavis S,Fletcher MD,et al.Functional role of matrix metallop rote inases in ovarian tumor cell plasticity[J].Am J Obstet Gynecol,2004,190(4):899-909.
[12]Dennie CJ,Veinot JP,McCormack DG,et al.Intimal sarcoma of the pulmonary arteries seen as a mosaic pattern of lung attenuation on high-resolution CT[J].AJR Am J Roentgenol,2002,178(5):1208-1210.
[13]Chang YS,de Tomaso E,McDonald DM,et al.Mosaic blood vessels in tumors:frequency of cancer ceils in contact with flowing blood[J].Proc Natc Acad Sei USA,2000,97(26):14608- 14613.
[14]Folkman J.Can mosaic tumor vessel facilitate molecular diagnosis of cancer?[J].Proc Natc Acad Sci USA,2001,98(2):398-400.
[15]张诗武,郭华,张丹芳,等.黑色素瘤组织内三种血液供应模式时间关系的初步探讨[J].中国肿瘤临床,2007,34(2):96-99.
[2]陈明伟,杨岚,倪磊,等.Rg3对人肺腺癌A549细胞及其内源性VEGF的影响[J].四川大学学报(医学版),2006;37(1):60-62.
[3]孙燕,林洪生,朱允中,等.长春瑞滨合并顺铂(NP)加参一胶囊或安慰剂治疗晚期非小细胞肺癌的多中心双盲随机临床研究报告[J].中国肺癌杂志,2006,9(3):254-258.
[4]American Cancer Society.Cancer Facts and Figueres 2006.Atlanta:American Cancer Sciety.2006:13-14.
[5]汤钊猷.现代肿瘤学[M],第2版上海:复旦大学出版社,2003,3.
[6]孙燕,周际昌.临床肿瘤内科手册[M],第4版北京:人民卫生出版社,2003:563-566.
[7]Martins SJ,Pereia JR.Clinical factors and prognosis in non-small cell lung cancer[J].Am J Clin Oncol,1999,22(5):453.
[8]Auerbach R,Lewis R,Shinners B,et al.Angiogensis assays:a critical overview[J].Clin Chem.2003,49(1):32-40.
[9]Hurvitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metasratic correctal cancer[J].Nev Engl J Med,2004,350(23):2335-2342.
[10]李树婷,孙燕.肿瘤血管抑制剂的研究历史,现状和发展前景[J].癌症进展,2003,6(1):801.
[11]Iishu H,Tatsuta M,Baba M,et al.Inhibition by ginsenoside Rg3 of bombesin induced by azoxymethane in Wistar rats[J].Clin Exp Metastasis,1997,15(6):603-611.
[12]史美祺,冯继峰,潘良熹,等.参一胶囊辅助化疗治疗晚期非小细胞肺癌临床观察[J].临床肿瘤学杂志,2006,11(3):193-194.
[13]陈明伟,杨岚,倪磊,等.Rg3对人肺腺癌A549细胞及其内源性VEGF的影响.四川大学学报(医学版),2006:37(1):60-62.
[14]Kato Y,Asano K,Mogi T,et al.Clinical significance of circulaxing vascular endothelial growth factor in dogs with mammarg gland tumors[J].Vet Med Sci,2007,69(1):77-80.
[15]Matsuyama W,Hashiguehi T,MizoguehiI A.Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer[J].Chest,2000,118(4):948-951.
[16]Shimanuki Y,Takahashi K,Cui R,et al.Role of serum vascular endothelial growth factor dependent in prediction of angiogenesis and prognosis for non-small cell lung cancer[J].Lung,2005,183(1):29-42.
[17]孙燕,石远凯.临床肿瘤内科手册[M],第5版北京:人民卫生出版社,2007:417-418.
[18]孙燕,石远凯.临床肿瘤内科手册[M],第5版北京:人民卫生出版社,2007:388.
[19]Non-small-cell Lung Cancer Collaborative Group:Chemotherapy in non-small-cell lung cancer:A meta-analysis using updated data on individual patients from 52 randomized clinical trials[J].British Medical Journal,1995,311(7010):899-909.
[20]吴银松,王臻.多西紫杉醇联合健择治疗晚期非小细胞肺癌的系列评价[]].第四军医大学学报,2004:25(3):278-281.
[21]臧爱华,于丁,柯玉华,等.我国晚期非小细胞肺癌化疗作用现状分析[J].中国肿瘤,2005,14(9):612.
[22]Folkman J,Beckner K,Angiogenesis imaging,Acad Radiol,2000,7(10):783-785.
[23]Sanderson RD.Heparan sulfate proteoglycans in vasion and metastasis[J].Semin Cell Dev Biol.2001.12(2).89.
[24]李树婷,孙燕.肿瘤血管抑制剂的研究历史、现状和发展前景[J].癌症进展,2003,1:80-87.
[25]王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究.中国肺癌杂志,2005,8(4):283-290.
[26]Tao X,Tang D.Advances in the study of tumor angiogenesis and anti-angiogenic Chinese herbal drugs[J].Chin Materia Medica,2003:26(5):379-381.
[27]Shinkai K,Akedo H,Mukai M,et al.Inhibition of in vitro tumor cell invasion by ginsenoside Rg3[J].Jpn J Cancer Res,1996;87(4):357-362.
[28]林洪生,李炳奎,李树奇.参一胶囊治疗肺癌Ⅱ期临床试验总结[J].中国肿瘤临床,2002,29(4):276-279.
[29]陈明伟,陈建,姚煜,等.人参皂甙20(R)-Rg3治疗肺癌的临床疗效观察[J].西安交通大学学报(医学版),2003,24(3):233.
[30]PerraraN,Davis-smyth T et al.Thebiology of vascular endothelial growth factor.Endocr Rev,1997,18:4-25.
[31]Park J,Keller GA,Ferrara N,et al.The vascular endothelial growth factor(VEGF)is of forms:differential deposition into thesubeithelial extracelluar matrix and bioactivity of extracelluar maxtrix-bound VEGF[J].Mol Biol Cell,1993,4:1317.
[32]张伟,王洁,刘叙仪,等.血管内皮生长因子/碱性成纤维细胞生长因子在非小细胞肺癌中的表达及临床意义[J].中国肿瘤临床,2002,29(4):5-9.
[33]吴宝新,邱志强,战忠利,等.MVD及VEGF、TGFβ-1表达与肺癌转移预后之间的关系[J].中国肿瘤临床,2003,30(10):21-24.
[34]余辉,吴一龙,戎铁华,等.p53、c-erB-2、VEGF蛋白表达对非小细胞肺癌辅助化疗的临床预测[J].中国肿瘤临床,2003,30(1):5-8.
[35]Nicosia RF.What is the role of vascular endothelial growth factor related molecules in tumor angiogenesis?[J].Am J Pathol,1998;153(1):11.
[36]Whittle C,Gillespie K,Harrison R,et al.Heterogeneous vascular endothelial growth factor(VEGF)isoform mRNA and receptor mRNA expression in human glomeruli,and the identification of VEGF148 Mrna,a novel truncated splice variant[J].Clin Sci(lond) 1999;97(3):303.
[37]董强刚,冯久贤,黄进肃,等.血管内皮生长因子对非小细胞肺癌血道转移的影响[J].中华肿瘤杂志,2002,24:142-146.
[38]朱玮.血管内皮生长因子(VEGF)在乳腺癌中的研究进展[J].中国临床医学,2003,(10)6:933-937.
[39]王友良,周民,陈涛.50例肺癌患者血清VEGF、p53含量的分析[J].现代肿瘤学,2005,13(6):811-812.
[40]蒋永新,伍治平,陈晓群,等.肺癌患者血清VEGF水平的临床研究[J].肿瘤防治研究,2005,32(8):526.
[41]朱光君,熊正文,李红伟,等.血管内皮生长因子在非小细胞肺癌中的表达及意义[J].实用医技杂志,2006,13(2):9-11.
[42]刘玉春,林士军,董惠翔,等.肺癌血清血管内皮生长因子水平与分期及预后的关系[J].中国肿瘤,2005,14(3):58-60.
[43]Tao X,Tang D.Advances in the study of tumor angiogenesis and anti-angiogenic Chinese herbal drugs.J Chin Materia Medica,2003:26(5):379-381.
[44]Shinkai K,Akedo H,Mukai M,et al.Inhibition of in vitro tumor cell invasion by ginsenoside Rg3.Jpn J Cancer Res,1996;87(4):357-362.
[45]Mochizuki M,Yoo YC,Matsuzawa K,et al.Inhibitory effect of tumor metastasis in mice by saponins,ginsenoside-Rb2,20(R)-2and20(S)-ginsenoside-Rg3 of red ginseng.Biol Pharm Bull 1995;18(9):1197-1202.
[46]高勇,王杰军,许青.人参皂甙Rg3抑制肿瘤新生血管形成机制研究.肿瘤防治究,2001,28(3):179-181.
[47]潘子民,叶大风,谢幸.人参皂甙Rg3对荷卵巢癌的严重联合免疫缺陷鼠的抗肿瘤血管生成作用的研究.中华妇产科杂志,2002,37(4):227.
[48]陈明伟,杨岚,倪磊,等.Rg3对人肺腺癌A549细胞及其内源性VEGF的影响.四川大学学报(医学版),2006;37(1):60-62.
[49]胡小梅,张培彤,杨宗燕,等.中晚期非小细胞肺癌患者中医证型分布规律研究[J].中国肿瘤,2007,16(1):51-53.
[1]Shimizu K,Asai T,Oku N.Antineovascular therapy,a novel antian-giogenic approach[J].Expert Op in Ther Targets,2005,9(1):63-76.
[2]Baillie C T,Winslet M C,Bradley N J.Tumor Vasculaturapotential therapeutic target[J].Br J Cancer,1995,27(3):257
[3]Rafii S,Lyden D,Benezra R,et al.Vascular and haematopoietic stem cells:novel targets for antiangio- genesis therapy? Nat Rev Cancer,2002,2(11):826-835
[4]Caduff JH,Fischer LC,Burri PH.Scanning electron microscope study of the devloping microvasculature in the postnatal rat lung.Anat Rec,1986,216(2):826-835
[5]Crivellato E,Nico B,Vacca A,et al.Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo.Leukemia,2004,18(2):331-336
[6]Burri PH,Hlushchuk R,Djonov V.Intussusceptive angiogenesis:its emergence,its characteristics,and its significance.Dev Dyn,2004,231(3):474-488
[7]Maniotis AJ,Folberg R,Hess A,et al.Vascular channel formation by human melanoma cells in vitro:vascuiogenie mimicry[J].Am J Parhol,1999,155(3):739-752
[8]Angela RH,Elisabeth AS,Lynn MG,et al.Molecular Regulation of Tumor Cell Vaseulogenic Mimicry by Tyrosine Phosphoryladon:Role of Epithelial Cell Kinase(Eck / EphA2)[J].Cancer Res,2001,61:3250-3255.
[9]Hendrix M J,Seftor E A,Hess A R,et al.Vasculogenic mimicry and tumour-cell plasticity:lessons from melanoma[J].Nat Rev Cancer,2003,3(6):411-421.
[10]Lee LM,Seftor EA,Bonde G,et al.The fate of human malignant melanoma cells transplanted into zebrafish embryos assessment of migration and cell division in the absence of tumor formation[J].Dev Dyn,2005,2334:1560-1570.
[11]Anil KS,Mavis S,Fletcher MD,et al.Functional role of matrix metallop rote inases in ovarian tumor cell plasticity[J].Am J Obstet Gynecol,2004,190(4):899-909.
[12]Dennie CJ,Veinot JP,McCormack DG,et al.Intimal sarcoma of the pulmonary arteries seen as a mosaic pattern of lung attenuation on high-resolution CT[J].AJR Am J Roentgenol,2002,178(5):1208-1210.
[13]Chang YS,de Tomaso E,McDonald DM,et al.Mosaic blood vessels in tumors:frequency of cancer ceils in contact with flowing blood[J].Proc Natc Acad Sei USA,2000,97(26):14608- 14613.
[14]Folkman J.Can mosaic tumor vessel facilitate molecular diagnosis of cancer?[J].Proc Natc Acad Sci USA,2001,98(2):398-400.
[15]张诗武,郭华,张丹芳,等.黑色素瘤组织内三种血液供应模式时间关系的初步探讨[J].中国肿瘤临床,2007,34(2):96-99.